Monday 4/5 Insider Buying Report: RCUS, PRPL

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.

So let's look at two noteworthy recent insider buys.

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.

So let's look at two noteworthy recent insider buys.

At Arcus Biosciences, a filing with the SEC revealed that on Wednesday, Director Kathryn E.

Falberg purchased 20,000 shares of RCUS, at a cost of $28.35 each, for a total investment of $566,996.

Falberg was up about 12.1% on the purchase at the high point of today's trading session, with RCUS trading as high as $31.79 in trading on Monday.

Arcus Biosciences is trading up about 10.3% on the day Monday.

And also on Wednesday, Director Gary Alan Kiedaisch purchased $149,800 worth of Purple Innovation, purchasing 5,000 shares at a cost of $29.96 a piece.

This purchase marks the first one filed by Kiedaisch in the past twelve months.

Purple Innovation is trading up about 4.2% on the day Monday.

Kiedaisch was up about 9.9% on the buy at the high point of today's trading session, with PRPL trading as high as $32.94 in trading on Monday.